Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors

Leuk Lymphoma. 2018 Mar;59(3):766-769. doi: 10.1080/10428194.2017.1357178. Epub 2017 Aug 9.

Authors

Emilie Cayssials^{1

2}, Florence Tartarin¹, Joëlle Guilhot¹, Nathalie Sorel³, Jean Claude Chomel³, Xavier Leleu^{1

2}, François Guilhot¹

Affiliations

¹ a INSERM CIC 1402 , CHU Poitiers , Poitiers , France.
² b Service d'Oncologie hématologique et Thérapie cellulaire , CHU Poitiers , Poitiers , France.
³ c Service de Cancérologie Biologique , CHU Poitiers , Poitiers , France.

PMID: 28792265
DOI: 10.1080/10428194.2017.1357178

No abstract available

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Male
Middle Aged
Prospective Studies
Protein Kinase Inhibitors / administration & dosage*
Remission Induction
Survival Rate
Treatment Outcome
Young Adult

Substances

Protein Kinase Inhibitors